Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)

(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023 · see citing works

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419 · see citing works

10-year follow-up of intensive glucose control in type 2 diabetes

Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · see citing works

Adipose Expression of Tumor Necrosis Factor-α: Direct Role in Obesity-Linked Insulin Resistance

Hotamisligil, G. S., Shargill, N. S., & Spiegelman, B. M. (1993) · Science · doi:10.1126/science.7678183 · Cited by 7,518 · see citing works

Global estimates of the prevalence of diabetes for 2010 and 2030

Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216 · see citing works

Inflammation and insulin resistance

Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769 · see citing works

Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation

Zanger, U. M., & Schwab, M. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.12.007 · Cited by 4,169 · see citing works

Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · see citing works

C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis

(2010) · The Lancet · doi:10.1016/s0140-6736(09)61717-7 · Cited by 2,546 · see citing works

Cytokines in Inflammatory Disease

Kany, S., Vollrath, J. T., & Relja, B. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20236008 · Cited by 2,027 · see citing works

Diabetes in Asia: Epidemiology, Risk Factors, and Pathophysiology

Chan, J. C. N., Malik, V., Jia, W., Kadowaki, T., Yajnik, C. S., Yoon, K.-H., & Hu, F. B. (2009) · JAMA · doi:10.1001/jama.2009.726 · Cited by 1,997 · see citing works

Clinical review of antidiabetic drugs: implications for type 2 diabetes mellitus management

Chaudhury, A., Duvoor, C., Reddy Dendi, V. S., Kraleti, S., Chada, A., Ravilla, R., Marco, A., Shekhawat, N. S., Montales, M. T., Kuriakose, K., et al. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00006 · Cited by 1,500 · see citing works

Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction

Martignoni, M., Groothuis, G. M. M., & de Kanter, R. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.6.875 · Cited by 1,478 · see citing works

Interleukin-6 in Biology and Medicine

Akira, S., Taga, T., & Kishimoto, T. (1993) · Advances in immunology · doi:10.1016/s0065-2776(08)60532-5 · Cited by 1,384 · see citing works

Diabetes Mellitus after Kidney Transplantation in the United States

Kasiske, B. L., Snyder, J. J., Gilbertson, D. T., & Matas, A. J. (2003) · American Journal of Transplantation · doi:10.1034/j.1600-6143.2003.00010.x · Cited by 1,286 · see citing works

NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X

Pickup, J. C., Mattock, M. B., Chusney, G. D., & Burt, D. J. (1997) · Diabetologia · doi:10.1007/s001250050822 · Cited by 1,231 · see citing works

Elevated Levels of Interleukin 6 Are Reduced in Serum and Subcutaneous Adipose Tissue of Obese Women after Weight Loss

Bastard, J., Jardel, C., Bruckert, É., Blondy, P., Capeau, J., Laville, M., Vidal, H., & Hainque, B. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.9.6839 · Cited by 1,102 · see citing works

Genetic contribution to variable human CYP3A-mediated metabolism

Lamba, J. K., Lin, Y. S., Schuetz, E. G., & Thummel, K. E. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00066-2 · Cited by 987 · see citing works

Identification of the Human Cytochrome P450 Enzymes Involved in the Two Oxidative Steps in the Bioactivation of Clopidogrel to Its Pharmacologically Active Metabolite

Kazui, M., Nishiya, Y., Ishizuka, T., Hagihara, K., Farid, N. A., Okazaki, O., Ikeda, T., & Kurihara, A. (2009) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029132 · Cited by 836 · see citing works

Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes Mellitus

Bolen, S. D., Feldman, L. S., Vassy, J. L., Wilson, L. M., Yeh, H., Marinopoulos, S. S., Wiley, C., Selvin, E., Wilson, R. F., Bass, E. B., et al. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-6-200709180-00178 · Cited by 816 · see citing works

The Aryl Hydrocarbon Receptor Complex and the Control of Gene Expression

Beischlag, T. V., Morales, J. L., Hollingshead, B. D., & Perdew, G. H. (2008) · Critical Reviews™ in Eukaryotic Gene Expression · doi:10.1615/critreveukargeneexpr.v18.i3.20 · Cited by 727 · see citing works

Cytochrome P450s and other enzymes in drug metabolism and toxicity

Guengerich, F. P. (2006) · The AAPS Journal · doi:10.1208/aapsj080112 · Cited by 623 · see citing works

High Blood Glucose Concentration Is a Risk Factor for Mortality in Middle-Aged Nondiabetic Men: 20-year follow-up in the Whitehall Study, the Paris Prospective Study, and the Helsinki Policemen Study

Balkau, B., Shipley, M. J., Jarrett, R. J., Pyörälà, K., Pyörälä, M., Forhan, A., & Eschwège, É. (1998) · Diabetes Care · doi:10.2337/diacare.21.3.360 · Cited by 597 · see citing works

Platelet Function Profiles in Patients With Type 2 Diabetes and Coronary Artery Disease on Combined Aspirin and Clopidogrel Treatment

Angiolillo, D. J., Fernández‐Ortíz, A., Bernardo, E., Ramírez, C., Sabaté, M., Jiménez‐Quevedo, P., Hernández, R., Moreno, R., Escaned, J., Alfonso, F., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2430 · Cited by 539 · see citing works

Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture.

Abdel‐Razzak, Z., Loyer, P., Fautrel, A., Gautier, J., Corcos, L., Turlin, B., Beaune, P. H., & Guillouzo, A. (1993) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13247-1 · Cited by 538 · see citing works

Impact of Infectious and Inflammatory Disease on Cytochrome P450–Mediated Drug Metabolism and Pharmacokinetics

Morgan, E. T. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.302 · Cited by 466 · see citing works

REGULATION OF DRUG-METABOLIZING ENZYMES AND TRANSPORTERS IN INFLAMMATION

Aitken, A. E., Richardson, T. A., & Morgan, E. T. (2005) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.46.120604.141059 · Cited by 449 · see citing works

Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and Cancer

Morgan, E. T., Goralski, K. B., Piquette‐Miller, M., Renton, K. W., Robertson, G. R., Chaluvadi, M. R., Charles, K. A., Clarke, S. J., Kacevska, M., Liddle, C., et al. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.018747 · Cited by 396 · see citing works

Cytochrome P-450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat.

Sattler, M., Guengerich, F. P., Yun, C., Christians, U., & Sewing, K. ‐. (1992) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08793-8 · Cited by 386 · see citing works

Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds

for the ADVANCE Collaborative Group, Zoungas, S., Chalmers, J., Ninomiya, T., Li, Q., Cooper, M. E., Colagiuri, S., Fulcher, G., de Galan, B. E., Harrap, S., et al. (2012) · Diabetologia · doi:10.1007/s00125-011-2404-1 · Cited by 358 · see citing works

Cyclosporin Clinical Pharmacokinetics

Fahr, A. (1993) · Clinical Pharmacokinetics · doi:10.2165/00003088-199324060-00004 · Cited by 357 · see citing works

Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention

Cavallari, L. H., Lee, C. R., Beitelshees, A. L., Cooper‐DeHoff, R. M., Duarte, J. D., Voora, D., Kimmel, S. E., McDonough, C. W., Gong, Y., Dave, C. V., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.07.022 · Cited by 315 · see citing works

Molecular Mechanisms of Tumor Necrosis Factor α Gene Expression in Monocytic Cells via Hyperglycemia-induced Oxidant Stress-dependent and -independent Pathways

Guha, M., Bai, W., Nadler, J. L., & Natarajan, R. D. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.23.17728 · Cited by 308 · see citing works

Regulation of the Acute Phase Response by Cytokines

Kushner, I. (1993) · Perspectives in biology and medicine · doi:10.1353/pbm.1993.0004 · Cited by 295 · see citing works

Glucose-Dependent Interleukin 6 and Tumor Necrosis Factor Production by Human Peripheral Blood Monocytes In Vitro

MOROHOSHI, M., Fujisawa, K., Uchimuraa, I., & Numano, F. (1996) · Diabetes · doi:10.2337/diab.45.7.954 · Cited by 281 · see citing works

Addressing phenoconversion: the Achilles' heel of personalized medicine

Shah, R. R., & Smith, R. L. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12441 · Cited by 278 · see citing works

Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture

Muntané-Relat, J., Ourlin, J.-C., Domergue, J., & Maurel, P. (1995) · Hepatology · doi:10.1002/hep.1840220420 · Cited by 241 · see citing works

Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus

Dharmalingam, M., & Yamasandhi, P. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_585_17 · Cited by 239 · see citing works

Interleukin-6 as a central mediator of cardiovascular risk associated with chronic inflammation, smoking, diabetes, and visceral obesity: down-regulation with essential fatty acids, ethanol and pentoxifylline

McCarty, M. F. (1999) · Medical Hypotheses · doi:10.1054/mehy.1997.0684 · Cited by 234 · see citing works

Peroxisome Proliferator-activated Receptor α Controls the Hepatic CYP4A Induction Adaptive Response to Starvation and Diabetes

Kroetz, D. L., Yook, P., Costet, P., Bianchi, P., & Pineau, T. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.47.31581 · Cited by 219 · see citing works

Cytochrome P450 and Liver Diseases

Villeneuve, J.-P., & Pichette, V. (2004) · Current Drug Metabolism · doi:10.2174/1389200043335531 · Cited by 219 · see citing works

The evolution of β‐cell dysfunction and insulin resistance in type 2 diabetes

Bergman, R., Finegood, D., & Kahn, S. (2002) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.32.s3.5.x · Cited by 217 · see citing works

Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo

Erlinge, D., Varenhorst, C., Braun, O. Ö., James, S., Winters, K. J., Jakubowski, J. A., Brandt, J. T., Sugidachi, A., Siegbahn, A., & Wallentin, L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.068 · Cited by 215 · see citing works

The pharmacokinetics and metabolic disposition of tacrolimus: A comparison across ethnic groups

Mancinelli, L. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.113183 · Cited by 206 · see citing works

Impact of CYP2C9 amino acid polymorphisms on glyburide kinetics and on the insulin and glucose response in healthy volunteers

Kirchheiner, J., Brockmöller, J., Meineke, I., Bauer, S., Rohde, W., Meisel, C., & Roots, I. (2002) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2002.122476 · Cited by 201 · see citing works

Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review

Klomp, S. D., Manson, M. L., Guchelaar, H., & Swen, J. J. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092890 · Cited by 200 · see citing works

Inflammation-Induced Phenoconversion of Polymorphic Drug Metabolizing Enzymes: Hypothesis with Implications for Personalized Medicine

Shah, R. R., & Smith, R. L. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061093 · Cited by 196 · see citing works

Effects of Interleukin-6 (IL-6) and an Anti-IL-6 Monoclonal Antibody on Drug-Metabolizing Enzymes in Human Hepatocyte Culture

Dickmann, L. J., Patel, S. K., Rock, D. A., Wienkers, L. C., & Slatter, J. G. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.038679 · Cited by 191 · see citing works

Interindividual Variability in Cytochrome P450–Mediated Drug Metabolism

Tracy, T. S., Chaudhry, A. S., Prasad, B., Thummel, K. E., Schuetz, E. G., Zhong, X., Tien, Y.-C., Jeong, H., Pan, X., Shireman, L. M., et al. (2015) · Drug Metabolism and Disposition · doi:10.1124/dmd.115.067900 · Cited by 181 · see citing works

Tumour necrosis factor‐alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors

Lechleitner, M., Koch, T., Herold, M., Dzien, A., & Hoppichler, F. (2000) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.2000.00705.x · Cited by 179 · see citing works

Novel Polymorphisms Associated With Tacrolimus Trough Concentrations: Results From a Multicenter Kidney Transplant Consortium

Jacobson, P. A., Oetting, W. S., Brearley, A. M., Leduc, R. E., Guan, W., Schladt, D., Matas, A. J., Lamba, V., Julian, B. A., Mannon, R. B., et al. (2011) · Transplantation · doi:10.1097/tp.0b013e318200e991 · Cited by 170 · see citing works

Insulin signaling in the transcriptional and posttranscriptional regulation of CYP2E1 expression

Woodcroft, K. J., Hafner, M. S., & NOVAK, R. F. (2002) · Hepatology · doi:10.1053/jhep.2002.30691 · Cited by 164 · see citing works

Changes in amounts of cytochrome P450 isozymes and levels of catalytic activities in hepatic and renal microsomes of rats with streptozocin-induced diabetes

Shimojo, N., Ishizaki, T., Imaoka, S., Funae, Y., Fuji, S., & Okuda, K. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90547-a · Cited by 163 · see citing works

A PASSION FOR P450s (REMEMBRANCES OF THE EARLY HISTORY OF RESEARCH ON CYTOCHROME P450)

Estabrook, R. W. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.12.1461 · Cited by 163 · see citing works

Voriconazole metabolism is influenced by severe inflammation: a prospective study

Veringa, A., ter Avest, M., Span, L. F. R., van den Heuvel, E. R., Touw, D. J., Zijlstra, J. G., Kosterink, J. G. W., van der Werf, T. S., & Alffenaar, J. C. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw349 · Cited by 163 · see citing works

Plasma levels of TNF-α and IL-6 are inversely related to cytochrome P450-dependent drug metabolism in patients with congestive heart failure

Frye, R. F., Schneider, V. M., Frye, C. S., & Feldman, A. M. (2002) · Journal of Cardiac Failure · doi:10.1054/jcaf.2002.127773 · Cited by 159 · see citing works

Relationship between serum tumor necrosis factor-α and insulin resistance in obese men with Type 2 diabetes mellitus

Mishima, Y., Kuyama, A., Tada, A., Takahashi, K., Ishioka, T., & Kibata, M. (2001) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(00)00247-3 · Cited by 159 · see citing works

Elevated Serum Sialic Acid Concentration in NIDDM and Its Relationship to Blood Pressure and Retinopathy

Crook, M. A., Tutt, P., & Pickup, J. C. (1993) · Diabetes Care · doi:10.2337/diacare.16.1.57 · Cited by 133 · see citing works

NAFLD and Diabetes: Two Sides of the Same Coin? Rationale for Gene-Based Personalized NAFLD Treatment

Xia, M., Bian, H., & Gao, X. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00877 · Cited by 133 · see citing works

Significantly reduced cytochrome P450 3A4 expression and activity in liver from humans with diabetes mellitus

Dostálek, M., Court, M. H., Yan, B., & Akhlaghi, F. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01270.x · Cited by 132 · see citing works

Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics

de Jong, L. M., Jiskoot, W., Swen, J. J., & Manson, M. L. (2020) · Genes · doi:10.3390/genes11121509 · Cited by 125 · see citing works

Nonalcoholic Fatty Liver Disease and Diabetes Are Associated with Decreased CYP3A4 Protein Expression and Activity in Human Liver

Jamwal, R., de la Monte, S. M., Ogasawara, K., Adusumalli, S., Barlock, B. J., & Akhlaghi, F. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00159 · Cited by 117 · see citing works

Therapeutic Approaches to Target Inflammation in Type 2 Diabetes

Goldfine, A. B., Fonseca, V. A., & Shoelson, S. E. (2010) · Clinical Chemistry · doi:10.1373/clinchem.2010.148833 · Cited by 116 · see citing works

High levels of circulating proinflammatory cytokines and leptin in urban, but not rural, Indians. A potential explanation for increased risk of diabetes and coronary heart disease.

Yudkin, J. S., Yajnik, C. S., Mohamed‐Ali, V., & Bulmer, K. (1999) · Diabetes Care · doi:10.2337/diacare.22.2.363 · Cited by 113 · see citing works

CYP2B6 genetic variants are associated with nevirapine pharmacokinetics and clinical response in HIV-1-infected children

Saitoh, A., Sarles, E., Capparelli, E. V., Aweeka, F. T., Kovács, A., Burchett, S. K., WIZNIA, A. A., Nachman, S., Fenton, T., & Spector, S. A. (2007) · AIDS · doi:10.1097/qad.0b013e3282ef9695 · Cited by 111 · see citing works

Increased Glucocorticoid Receptor and 11β-Hydroxysteroid Dehydrogenase Type 1 Expression in Hepatocytes May Contribute to the Phenotype of Type 2 Diabetes in db/db Mice

Liu, Y., Nakagawa, Y., Wang, Y., Sakurai, R., Tripathi, P. V., Lutfy, K., & Friedman, T. C. (2005) · Diabetes · doi:10.2337/diabetes.54.1.32 · Cited by 111 · see citing works

Effects of interleukin-6 on cytochrome P450-dependent mixed-function oxidases in the rat

Chen, Y. L., Florentin, I., Batt, A., Ferrari, L., Giroud, J., & Chauvelot‐Moachon, L. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90047-m · Cited by 110 · see citing works

Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing

Kacevska, M., Robertson, G. R., Clarke, S. J., & Liddle, C. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.2.137 · Cited by 104 · see citing works

Hepatic cytochrome P-450j induction in the spontaneously diabetic BB rat.

Bellward, G. D., Chang, T., Rodrigues, B. B., McNeill, J. H., Maines, S. L., Ryan, D. E., Levin, W., & Thomas, P. E. (1988) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)13127-1 · Cited by 104 · see citing works

Antidiabetic Medications and Polypharmacy

Peron, E. P., Ogbonna, K. C., & Donohoe, K. L. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.08.017 · Cited by 103 · see citing works

The Glucocorticoid Receptor Is Essential for Induction of Cytochrome P-4502B by Steroids but Not for Drug or Steroid Induction of CYP3A or P-450 Reductase in Mouse Liver

Schuetz, E. G., Schmid, W., Schütz, G., Brimer, C., Yasuda, K., Kamataki, T., Bornheim, L. M., Myles, K. M., & Cole, T. J. (2000) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(24)15361-5 · Cited by 101 · see citing works

Genetic polymorphisms in cytochrome P450 oxidoreductase influence microsomal P450-catalyzed drug metabolism

Hart, S. N., Wang, S., Nakamoto, K., Wesselman, C., Li, Y., & Zhong, X.-B. (2008) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0b013e3282f2f121 · Cited by 99 · see citing works

Metabolic properties of the acid and lactone forms of HMG-CoA reductase inhibitors

Fujino, H., Saito, T., Tsunenari, Y., Kojima, J., & Sakaeda, T. (2004) · Xenobiotica · doi:10.1080/00498250400015319 · Cited by 98 · see citing works

Insulin effects on CYP2E1, 2B, 3A, and 4A expression in primary cultured rat hepatocytes

Woodcroft, K. J., & NOVAK, R. F. (1997) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00075-6 · Cited by 95 · see citing works

Secretion of tumor necrosis factor-alpha shows a strong relationship to insulin-stimulated glucose transport in human adipose tissue.

Löfgren, P., van Harmelen, V., Reynisdottir, S., Näslund, E. B., Rydén, M., Rössner, S. M., & Arner, P. (2000) · Diabetes · doi:10.2337/diabetes.49.5.688 · Cited by 91 · see citing works

Effects of testosterone and growth hormone treatment on hepatic microsomal P450 expression in the diabetic rat.

Thummel, K. E., & Schenkman, J. B. (1990) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09941-9 · Cited by 88 · see citing works

Induction of cytochrome P450III and P450IV family proteins in streptozotocin-induced diabetes

Barnett, C. R., Gibson, G. G., Wolf, C. R., Flatt, P. R., & Ioannides, C. (1990) · Biochemical Journal · doi:10.1042/bj2680765 · Cited by 87 · see citing works

Modulation of CYP 450 Activities in Patients With Type 2 Diabetes

Gravel, S., Chiasson, J., Turgeon, J., Grangeon, A., & Michaud, V. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1496 · Cited by 84 · see citing works

Hypoglycemia Increases Serum Interleukin-6 Levels in Healthy Men and Women

Dotson, S., Freeman, R. L., Failing, H. J., & Adler, G. K. (2008) · Diabetes Care · doi:10.2337/dc07-2243 · Cited by 79 · see citing works

Evaluation of the Influence of Diabetes Mellitus on Antipyrine Metabolism and CYP1A2 and CYP2D6 Activity

Matzke, G. R., Frye, R. F., Early, J. J., Straka, R. J., & Carson, S. W. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.3.182.34775 · Cited by 75 · see citing works

Proinflammatory cytokines are increased in type 2 diabetic women with cardiovascular disease

Tuttle, H. A., Davis‐Gorman, G., Goldman, S., Copeland, J. G., & McDonagh, P. F. (2004) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(03)00088-6 · Cited by 73 · see citing works

A discordance of the cytochrome P450 2C19 genotype and phenotype in patients with advanced cancer

Williams, M. L., Bhargava, P., Cherrouk, I., Marshall, J. L., Flockhart, D. A., & Wainer, I. W. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00189.x · Cited by 73 · see citing works

Pharmacokinetics of theophylline in diabetes mellitus rats: Induction of CYP1A2 and CYP2E1 on 1,3-dimethyluric acid formation

Kim, Y. C., Lee, A. K., Lee, J. H., Lee, I., Lee, D., Kim, S. H., Kim, S. G., & Lee, M. G. (2005) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.05.004 · Cited by 72 · see citing works

Hyperglycaemia and coronary heart disease: The Whitehall Study

Fuller, J., McCartney, P., Jarrett, R. J., Keen, H., Rose, G., Shipley, M. J., & Hamilton, P. J. S. (1979) · Journal of Chronic Diseases · doi:10.1016/0021-9681(79)90051-1 · Cited by 70 · see citing works

Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population

Bathum, L., Skjelbo, E., Mutabingwa, T. K., Madsen, H., Hørder, M., & Brøsen, K. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00019.x · Cited by 69 · see citing works

Immunological Response as a Source to Variability in Drug Metabolism and Transport

Christensen, H., & Hermann, M. (2012) · Frontiers in Pharmacology · doi:10.3389/fphar.2012.00008 · Cited by 69 · see citing works

Mechanisms and Outcomes of Drug- and Toxicant-Induced Liver Toxicity in Diabetes

Wang, T., Shankar, K., Ronis, M. J. J., & Mehendale, H. M. (2007) · Critical Reviews in Toxicology · doi:10.1080/10408440701215100 · Cited by 68 · see citing works

Metabolism of thalidomide in human microsomes, cloned human cytochrome P-450 isozymes, and Hansen?s disease patients

Teo, S. K., Sabourin, P. J., O'Brien, K., Kook, K. A., & Thomas, S. D. (2000) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/(sici)1099-0461(2000)14:3 · Cited by 67 · see citing works

CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype

Helsby, N. A., Lo, W.-Y., SHARPLES, K. J., Riley, G., Murray, M., Spells, K. P., Dzhelai, M., Simpson, A., & Findlay, M. P. N. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604699 · Cited by 65 · see citing works

REDUCTION OF BLOOD FIBRINOLYTIC ACTIVITY IN DIABETES MELLITUS BY INSULIN

Fearnley, G. R., Vincent, C., & Chakrabarti, R. (1959) · The Lancet · doi:10.1016/s0140-6736(59)91534-x · Cited by 61 · see citing works

Composition Changes in Hepatic Microsomal Cytochrome P-450 During Onset of Streptozocin-Induced Diabetes and During Insulin Treatment

Favreau, L. V., & Schenkman, J. B. (1988) · Diabetes · doi:10.2337/diab.37.5.577 · Cited by 61 · see citing works

Interferon suppresses erythromycin metabolism in rats and human subjects

Craig, P. I., Tapner, M. J., & Farrell, G. C. (1993) · Hepatology · doi:10.1002/hep.1840170212 · Cited by 59 · see citing works

Insulin in flavin-containing monooxygenase regulation

Borbás, T., Benkő, B., Dalmadi, B., Szabó, I., & Tihanyi, K. (2006) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2005.12.011 · Cited by 54 · see citing works

Cytochrome P450 1A2 (CYP1A2) activity and risk factors for breast cancer: a cross-sectional study

Hong, C., Tang, B.-K., Hammond, G. L., Tritchler, D., Yaffe, M. J., & Boyd, N. F. (2004) · Breast Cancer Research · doi:10.1186/bcr798 · Cited by 54 · see citing works

Assessment of CYP1A2 enzyme activity in relation to type-2 diabetes and habitual caffeine intake

Urry, E., Jetter, A., & Landolt, H. (2016) · Nutrition & Metabolism · doi:10.1186/s12986-016-0126-6 · Cited by 54 · see citing works

Effect of recombinant human interleukin-1 beta and tumor necrosis factor alpha on liver cytochrome P-450 and serum alpha-1-acid glycoprotein concentrations in the rat.

Poüs, C., Giroud, J., Damais, C., Raichvarg, D., & Chauvelot‐Moachon, L. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08541-1 · Cited by 51 · see citing works

Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics–small molecule drug interactions

Mallick, P., Taneja, G., Moorthy, B., & Ghose, R. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1292251 · Cited by 50 · see citing works

The effect of clopidogrel on platelet activity in patients with and without type-2 diabetes mellitus: a comparative study

Schütte, C., Steffens, D., Witkowski, M., Stellbaum, C., Bobbert, P., Schultheiss, H., & Rauch, U. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0182-7 · Cited by 49 · see citing works

Determination of glibenclamide and its two major metabolites in human serum and urine by column liquid chromatography

Rydberg, T., Wahlin‐Boll, E., & Melander, A. (1991) · Journal of Chromatography B Biomedical Sciences and Applications · doi:10.1016/0378-4347(91)80084-p · Cited by 48 · see citing works

Opposite Effect of Diabetes Mellitus Induced by Streptozotocin on Oral and Intravenous Pharmacokinetics of Verapamil in Rats

Hu, N., Xie, S., Liu, L., Wang, X., Pan, X., Chen, G., Zhang, L., Liu, H., Liu, X., Liu, X., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035642 · Cited by 48 · see citing works

Dynamic and kinetic disposition of nisoldipine enantiomers in hypertensive patients presenting with type-2 diabetes mellitus

Marques, M. P., Coelho, E. B., dos Santos, N. A. G., Geleilete, T. J. M., & Lanchote, V. L. (2002) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-002-0528-4 · Cited by 47 · see citing works

In VivoMetabolic Activity of CYP2C19 and CYP3A in Relation to CYP2C19 Genetic Polymorphism in Chronic Liver Disease

Ohnishi, A., MURAKAMI, S., Akizuki, S., Mochizuki, J., Echizen, H., & Takagi, I. (2005) · The Journal of Clinical Pharmacology · doi:10.1177/0091270005280787 · Cited by 47 · see citing works

Hormonal regulation of microsomal cytochrome P4502E1 and P450 reductase in rat liver and kidney

CHEN, G.-F., Ronis, M. J. J., Ingelman‐Sundberg, M., & Badger, T. M. (1999) · Xenobiotica · doi:10.1080/004982599238461 · Cited by 47 · see citing works

Cytochrome P450 changes in rats with streptozocin-induced diabetes

Nobuo, S. (1994) · International Journal of Biochemistry · doi:10.1016/0020-711x(94)90095-7 · Cited by 46 · see citing works

Diabetes and Elimination of Antipyrine in Man: An Analysis of 298 Patients Classified by Type of Diabetes, Age, Sex, Duration of Disease and Liver Involvement*

Sotaniemi, E. A., Pelkonen, O., Arranto, A. J., Tapanainen, P. J., Rautio, A., & Pasanen, M. (2002) · Pharmacology & Toxicology · doi:10.1034/j.1600-0773.2002.900308.x · Cited by 42 · see citing works

Toxicity of diazinon and its metabolites increases in diabetic rats

Ueyama, J., Wang, D., Kondo, T., Saito, I., Takagi, K., Takagi, K., Kamijima, M., Nakajima, T., Miyamoto, K., Wakusawa, S., et al. (2007) · Toxicology Letters · doi:10.1016/j.toxlet.2007.03.010 · Cited by 39 · see citing works

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention

Sweeny, J. M., Angiolillo, D. J., Franchi, F., Rollini, F., Waksman, R., Raveendran, G., Dangas, G., Khan, N. D., Carlson, G. F., Zhao, Y., et al. (2017) · Journal of the American Heart Association · doi:10.1161/jaha.117.005650 · Cited by 38 · see citing works

Expression and Functional Analysis of Hepatic Cytochromes P450, Nuclear Receptors, and Membrane Transporters in 10- and 25-Week-Old db/db Mice

Lam, J. L., Jiang, Y., Zhang, T., Zhang, E. Y., & Smith, B. J. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.034223 · Cited by 37 · see citing works

Differential effects of cytokines on the inducible expression of cyp1a1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture*1

Muntané-Relat, J. (1995) · Hepatology · doi:10.1016/0270-9139(95)90622-3 · Cited by 37 · see citing works

Variability of clopidogrel response in patients with type 2 diabetes mellitus

Hall, H. M., Banerjee, S., & McGuire, D. K. (2011) · Diabetes and Vascular Disease Research · doi:10.1177/1479164111420890 · Cited by 36 · see citing works

Acetoacetate Induces CYP2E1 Protein and Suppresses CYP2E1 mRNA in Primary Cultured Rat Hepatocytes

Abdelmegeed, M. A., Carruthers, N. J., Woodcroft, K. J., Kim, S. K., & NOVAK, R. F. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.084608 · Cited by 35 · see citing works

Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms

Pacanowski, M. A., Hopley, C. W., & Aquilante, C. L. (2008) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.4.5.529 · Cited by 35 · see citing works

High glucose concentrations increase the tumor necrosis factor-alpha production capacity by human peripheral blood mononuclear cells.

Hâncu, N., Netea, M. G., & Baciu, I. (2000) · PubMed · Cited by 35 · see citing works

Combined Contributions of Impaired Hepatic CYP2C11 and Intestinal Breast Cancer Resistance Protein Activities and Expression to Increased Oral Glibenclamide Exposure in Rats with Streptozotocin-Induced Diabetes Mellitus

Liu, H., Liu, L., Li, J., Mei, D., Duan, R., Hu, N., Guo, H., Zhong, Z., & Liu, X. (2012) · Drug Metabolism and Disposition · doi:10.1124/dmd.111.043513 · Cited by 34 · see citing works

Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues

Maximos, S., Chamoun, M., Gravel, S., Turgeon, J., & Michaud, V. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9040040 · Cited by 32 · see citing works

Prediction of Atorvastatin Pharmacokinetics in High-Fat Diet and Low-Dose Streptozotocin-Induced Diabetic Rats Using a Semiphysiologically Based Pharmacokinetic Model Involving Both Enzymes and Transporters

Wang, Z., Yang, H., Xu, J., Zhao, K., Yang, C., Liang, L., Li, P., Chen, N., Geng, D., Zhang, X., et al. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.085902 · Cited by 32 · see citing works

Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus

Moisés, E. C. D., Duarte, L. D. B., Cavalli, R. D. C., Marques, M. P., Lanchote, V. L., Duarte, G. G., & da Cunha, S. P. (2008) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-008-0544-0 · Cited by 31 · see citing works

The Concentration of Cyclosporine Metabolites Is Significantly Lower in Kidney Transplant Recipients With Diabetes Mellitus

Akhlaghi, F., Dostálek, M., Falck, P., Mendonza, A. E., Amundsen, R., Gohh, R., & Åsberg, A. (2011) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0b013e318241ac71 · Cited by 31 · see citing works

Pharmacokinetics of verapamil in diabetic rats induced by combination of high-fat diet and streptozotocin injection

Chen, G., Hu, N., Liu, L., Xie, S., Wang, P., Jun, L. I., Xie, L. Y., Wang, G., & Liu, X.-D. (2011) · Xenobiotica · doi:10.3109/00498254.2011.558933 · Cited by 31 · see citing works

Pharmacogenetics in diabetes

Pearson, E. R. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0028-3 · Cited by 31 · see citing works

Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice

Manolopoulos, V. G. (2007) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2007.184 · Cited by 30 · see citing works

Changes in omeprazole pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: Faster clearance of omeprazole due to induction of hepatic CYP1A2 and 3A1

Lee, D. Y., Lee, M. G., Shin, H. S., & Lee, I. (2007) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3wc7g · Cited by 30 · see citing works

Difference in the Pharmacokinetics and Hepatic Metabolism of Antidiabetic Drugs in Zucker Diabetic Fatty and Sprague-Dawley Rats

Zhou, X., Rougée, L. R. A., Bedwell, D. W., Cramer, J. W., Mohutsky, M. A., Calvert, N. A., Moulton, R., Cassidy, K. C., Yumibe, N. P., Adams, L. A., et al. (2016) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.070623 · Cited by 28 · see citing works

In vitro effects of tacrolimus on human cytochrome P450

Lecointre, K., Furlan, V., & Taburet, A. M. (2002) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2002.00114.x · Cited by 25 · see citing works

Relationship Between Serum Concentrations of Interleukin-6 and Tumor Necrosis Factor Alpha in Female Turkish Subjects with Normal and Impaired Glucose Tolerance

Konukoğlu, D., Hâtemi, H., Bayer, H., & Bagriacik, N. (2006) · Hormone and Metabolic Research · doi:10.1055/s-2006-924974 · Cited by 25 · see citing works

Effect of experimental diabetes on pharmacokinetic parameters of lidocaine and MEGX in rats.

Gawronska-Szklarz, B., Musiał, D. H., Pawlik, A., & Paprota, B. (2003) · PubMed · Cited by 23 · see citing works

Effect of Diabetes Mellitus on the Metabolism of Drugs and Toxins

Houshang, M. V. A. (2015) · Journal of Clinical Toxicology · doi:10.4172/2161-0495.1000233 · Cited by 23 · see citing works

Differences in the pharmacokinetics of Cyp3a substrates in TSOD and streptozotocin-induced diabetic mice

Kudo, T., Toda, T., Ushiki, T., Ohi, K., Ikarashi, N., Ochiai, W., & Sugiyama, K. (2010) · Xenobiotica · doi:10.3109/00498251003596809 · Cited by 21 · see citing works

CYP2C19 genotype–phenotype discordance in patients with multiple myeloma leads to an acquired loss of drug-metabolising activity

Burns, K. E., Goldthorpe, M. A., Porteus, F., Browett, P., & Helsby, N. A. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2409-9 · Cited by 20 · see citing works

Pharmacokinetics of diclofenac in rat model of diabetes mellitus induced by alloxan or steptozotocin

Kim, Y. C., Oh, E. Y., Kim, S. H., & Lee, M. G. (2005) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.484 · Cited by 20 · see citing works

Effects of vanadate on hepatic cytochrome P-450 expression in streptozotocin-diabetic rats.

Donahue, B. S., & Morgan, E. T. (1990) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08550-2 · Cited by 20 · see citing works

Altered Protein Expression of Cardiac CYP2J and Hepatic CYP2C, CYP4A, and CYP4F in a Mouse Model of Type II Diabetes—A Link in the Onset and Development of Cardiovascular Disease?

Drolet, B., Pilote, S., Gélinas, C., Kamaliza, A.-D., Blais-Boilard, A., Virgili, J., Patoine, D., & Simard, C. (2017) · Pharmaceutics · doi:10.3390/pharmaceutics9040044 · Cited by 19 · see citing works

Blood and Plasma Pharmacokinetics of Ciclosporin in Diabetic Kidney Transplant Recipients

Mendonza, A. E., Gohh, R., & Akhlaghi, F. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847110-00004 · Cited by 17 · see citing works

Hypoglycaemia downregulates endotoxin-induced production of tumour necrosis factor-α, but does not affect IL-1β, IL-6, or IL-10

de Galan, B. E., Netea, M. G., Smits, P., & van der Meer, J. W. M. (2003) · Cytokine · doi:10.1016/s1043-4666(03)00113-3 · Cited by 16 · see citing works

Pharmacokinetics of oltipraz in rat models of diabetes mellitus induced by alloxan or streptozotocin

Bae, S. K., Kim, J. Y., Yang, S., Kim, J. W., Kim, T., & Lee, M. G. (2005) · Life Sciences · doi:10.1016/j.lfs.2005.09.031 · Cited by 16 · see citing works

Theophylline metabolism in healthy nonsmokers and in patients with insulin-dependent diabetes mellitus*

Korrapati, M. R., Vestal, R. E., & Loi, C. (1995) · Clinical Pharmacology & Therapeutics · doi:10.1016/0009-9236(95)90210-4 · Cited by 16 · see citing works

Impairment of Intestinal Monocarboxylate Transporter 6 Function and Expression in Diabetic Rats Induced by Combination of High-Fat Diet and Low Dose of Streptozocin: Involvement of Butyrate–Peroxisome Proliferator-Activated Receptor-γ Activation

Xu, F., Zhu, L., Qian, C.-Q., Zhou, J., Geng, D., Li, P., Xuan, W., Wu, F., Zhao, K., Kong, W., et al. (2019) · Drug Metabolism and Disposition · doi:10.1124/dmd.118.085803 · Cited by 15 · see citing works

Clopidogrel Resistance in a Murine Model of Diet-Induced Obesity Is Mediated by the Interleukin-1 Receptor and Overcome With DT-678

Sun, Y., Venugopal, J., Guo, C., Fan, Y., Li, J., Gong, Y., Chen, Y. E., Zhang, H., & Eitzman, D. T. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314146 · Cited by 14 · see citing works

Phenocopy and Phenoconversion: Do they Complicate Association Studies?

Shah, R. R., & Smith, R. L. (2012) · Pharmacogenomics · doi:10.2217/pgs.12.71 · Cited by 12 · see citing works

Glyburide Metabolism by Placentas of Healthy and Gestational Diabetics

Jain, S., Zharikova, O. L., Ravindran, S., Nanovskya, T., Mattison, D. R., Hankins, G., & Ahmed, M. (2008) · American Journal of Perinatology · doi:10.1055/s-2008-1061503 · Cited by 11 · see citing works

Evaluation of changes in cytochrome P450 2C19 activity in type 2 diabetic rats before and after treatment, by using isolated perfused liver model.

Neyshaburinezhad, N., Rouini, M. R., Entezari, H., Lavasani, H., & Ardakani, Y. H. (2020) · PubMed Central · doi:10.22038/ijbms.2020.40836.9642 · Cited by 11 · see citing works

Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients

Bogman, K., Silkey, M., Chan, S. P., Tomlinson, B., & Weber, C. (2010) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-010-0840-3 · Cited by 10 · see citing works

Expression and activity of CYP2E1 in circulating lymphocytes are not altered in diabetic individuals

Pucci, L., Chirulli, V., Marini, S., Lucchesi, D., Penno, G., Gervasi, P. G., Prato, S. D., & Longo, V. G. (2005) · Pharmacological Research · doi:10.1016/j.phrs.2005.02.005 · Cited by 9 · see citing works

Pharmacokinetics of phenytoin and its metabolite, 4′‐HPPH, after intravenous and oral administration of phenytoin to diabetic rats induced by alloxan or streptozotocin

Kim, Y. C., Kang, H. E., & Lee, M. G. (2007) · Biopharmaceutics & Drug Disposition · doi:10.1002/bdd.591 · Cited by 8 · see citing works

Cyclosporine Metabolites’ Metabolic Ratios May Be Markers of Cardiovascular Disease in Kidney Transplant Recipients Treated with Cyclosporine A-Based Immunosuppression Regimens

Hryniewiecka, E., Żegarska, J., Żochowska, D., Samborowska, E., Jaźwiec, R., Kosieradzki, M., Nazarewski, S., Dadlez, M., & Pączek, L. (2018) · Cardiovascular Toxicology · doi:10.1007/s12012-018-9492-9 · Cited by 5 · see citing works

Insulin-mimetic effects of vanadate in preventing the increase of P450IIIA and P450IA subfamily proteins in streptozotocin-diabetic rats

Verrecchia, A., & GUAITANI, A. (1993) · Acta Diabetologica · doi:10.1007/bf00572855 · Cited by 3 · see citing works

Induction of Diabetes Abolishes the Antithrombotic Effect of Clopidogrel in Apolipoprotein E–Deficient Mice

Sugidachi, A., Ohno, K., Jakubowski, J. A., Ito, Y., Tomizawa, A., & Mizuno, M. (2017) · TH Open · doi:10.1055/s-0037-1605361 · Cited by 3 · see citing works

Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections

González, P., Lozano, P., Ros, G., & Solano, F. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119352 · Cited by 891 · see citing works

The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials

Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., Zhang, C., Wang, Y., & Liu, W. J. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/2074610 · Cited by 110 · see citing works

Influence of Inflammation on Cytochromes P450 Activity in Adults: A Systematic Review of the Literature

Lenoir, C., Rollason, V., Desmeules, J. A., & Samer, C. F. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.733935 · Cited by 106 · see citing works

The Role of CYP3A in Health and Disease

Klyushova, L. S., Perepechaeva, M. L., & Grishanova, A. Y. (2022) · Biomedicines · doi:10.3390/biomedicines10112686 · Cited by 105 · see citing works

Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions

Armani, S., Geier, A., Forst, T. M., Merle, U., Alpers, D., & Lunnon, M. W. (2023) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15990 · Cited by 73 · see citing works

Inflammation-Driven Genomic Instability: A Pathway to Cancer Development and Therapy Resistance

Rembiałkowska, N., Kocik, Z., Kłosińska, A., Kübler, M., Pałkiewicz, A., Rozmus, W., Sędzik, M., Wojciechowska, H., & Gajewska-Naryniecka, A. (2025) · Pharmaceuticals · doi:10.3390/ph18091406 · Cited by 41 · see citing works

The impact of CYP2C19 genotype on phenoconversion by concomitant medication

de Jong, L. M., Boussallami, S., Sánchez-López, E., Giera, M. A., Tushuizen, M. E., Hoekstra, M., Hawinkels, L. J. A. C., Rißmann, R., Swen, J. J., & Manson, M. L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1201906 · Cited by 33 · see citing works

Contribution of CYP2D6 Functional Activity to Oxycodone Efficacy in Pain Management: Genetic Polymorphisms, Phenoconversion, and Tissue-Selective Metabolism

Deodhar, M., Turgeon, J., & Michaud, V. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091466 · Cited by 30 · see citing works

The Significance of Systemic Immune-Inflammatory Index for Mortality Prediction in Diabetic Patients Treated with Off-Pump Coronary Artery Bypass Surgery

Urbanowicz, T. K., Michalak, M., Al-Imam, A., Olasińska‐Wiśniewska, A., Rodzki, M., Witkowska, A., Haneya, A., Buczkowski, P., Perek, B., & Jemielity, M. (2022) · Diagnostics · doi:10.3390/diagnostics12030634 · Cited by 30 · see citing works

Influence of metabolic state and body composition on the action of pharmacological treatment of migraine

Bruijn, N., van Lohuizen, R., Boron, M., Fitzek, M. P., Gabriele, F., Giuliani, G., Melgarejo, L., Řehulka, P., Sebastianelli, G., Triller, P., et al. (2024) · The Journal of Headache and Pain · doi:10.1186/s10194-024-01724-3 · Cited by 23 · see citing works

Novel mediators regulating angiogenesis in diabetic foot ulcer healing

Rai, V., Le, H., & Agrawal, D. K. (2023) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2023-0193 · Cited by 21 · see citing works

Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report

Toro-Pagán, N. M. D., Matos, A., Bardolia, C., Michaud, V., Turgeon, J., & Amin, N. S. (2022) · BMC Psychiatry · doi:10.1186/s12888-021-03659-4 · Cited by 18 · see citing works

Molecular biochemical aspects of salt (sodium chloride) in inflammation and immune response with reference to hypertension and type 2 diabetes mellitus

Das, U. N. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01507-8 · Cited by 16 · see citing works

Genome-wide microRNA profiles identify miR-107 as a top miRNA associating with expression of the CYP3As and other drug metabolizing cytochrome P450 enzymes in the liver

Tantawy, M., Collins, J. M., & Wang, D. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.943538 · Cited by 14 · see citing works

Exposure to per- and poly-fluoroalkyl substances in association to later occurrence of type 2 diabetes and metabolic pathway dysregulation in a multiethnic US population

Midya, V., Yao, M., Colicino, E., Barupal, D. K., Lin, X., Gennings, C., Chatzi, L., Setiawan, V. W., Loos, R. J. F., Walker, R. W., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105838 · Cited by 12 · see citing works

A meta-analysis of genome-wide gene expression differences identifies promising targets for type 2 diabetes mellitus

Huang, T., Nazir, B., Altaf, R., Zang, B., Zafar, H., Paiva‐Santos, A. C., Niaz, N., Imran, M., Duan, Y., Abbas, M., et al. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.985857 · Cited by 12 · see citing works

Chronic Lung Disease as a Risk Factor for Long COVID in Patients Diagnosed With Coronavirus Disease 2019: A Retrospective Cohort Study

Zhang, X., Anzalone, A. J., Dai, D., Cochran, G. L., Dai, R., Rupp, M. E., Collaborative, F. T. N. C. C. (., Wilcox, A. B., Lee, A. M., Graves, A., et al. (2024) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae424 · Cited by 10 · see citing works

Extraction and Evaluation of Bioactive Compounds from Immature and Mature Corn Silk

Khushe, K. J., Wazed, M. A., Islam, M. R., Awal, M. S., & Mozumder, N. H. M. R. (2024) · Journal of Food Quality · doi:10.1155/2024/9552151 · Cited by 9 · see citing works

Network medicine based approach for identifying the type 2 diabetes, osteoarthritis and triple negative breast cancer interactome: Finding the hub of hub genes

Durrani, I. A., John, P., Bhatti, A., & Khan, J. S. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e36650 · Cited by 8 · see citing works

Identification of chemical constituents of Qingjin Yiqi granules and comparative study on pharmacokinetics of 23 main bioactive components in normal and Lung-Qi deficiency rats by UPLC-MS/MS method

Li, G., Wang, X., Luo, L., Zhang, H., Song, X., Zhang, J., & Liu, D. (2023) · Journal of Chromatography B · doi:10.1016/j.jchromb.2023.123802 · Cited by 8 · see citing works

Mechanisms of altered hepatic drug disposition during pregnancy: small molecules

Fashe, M. M., Tiley, J. B., & Lee, C. R. (2025) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2025.2470792 · Cited by 7 · see citing works

Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report

Toro-Pagán, N. M. D., Matos, A., Thacker, D. L., Turgeon, J., Amin, N. S., & Michaud, V. (2021) · Medicina · doi:10.3390/medicina57090955 · Cited by 7 · see citing works

A systematic review on disease‐drug‐drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling

de Jong, L. M., Klomp, S. D., Treijtel, N., Rißmann, R., Swen, J. J., & Manson, M. L. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15372 · Cited by 7 · see citing works

Metabonomic Characteristics of Myocardial Diastolic Dysfunction in Type 2 Diabetic Cardiomyopathy Patients

Hao, M., Deng, J., Huang, X., Li, H., Ou, H., Cai, X., She, J., Liu, X., Chen, L., Chen, S., et al. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.863347 · Cited by 7 · see citing works

Multidrug Interactions: Why Do They Occur and How to Handle?

Dow, P., Michaud, V., & Turgeon, J. (2023) · Clinical Therapeutics · doi:10.1016/j.clinthera.2022.12.012 · Cited by 7 · see citing works

Establishment of a mathematical prediction model for voriconazole stable maintenance dose: a prospective study

Zhou, L., Li, M., Li, H., Guo, Z., Gao, Y., Zhang, H., Qin, F., Sang, Z., Xing, Q., Cheng, L., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1157944 · Cited by 7 · see citing works

A model‐informed approach to accelerate the clinical development of cofrogliptin ( HSK7653 ), a novel ultralong‐acting dipeptidyl peptidase‐4 inhibitor

Cui, C., Cao, F., Kong, I. I., Qing-he, W., Li, F., Li, H., & Liu, D. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15348 · Cited by 6 · see citing works

Synergistic effects of overweight/obesity and high hemoglobin A1c status on elevated high-sensitivity C-reactive protein in Chinese adults: a cross-sectional study

Shen, Q., He, T., Li, T., Szeto, I. M., Mao, S., Zhong, W., Li, P., Jiang, H., & Zhang, Y. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1156404 · Cited by 6 · see citing works

Microbiota dysbiosis associated with type 2 diabetes-like effects caused by chronic exposure to a mixture of chlorinated persistent organic pollutants in zebrafish

Lee, H., Yoon, S., Park, Y. H., Lee, J.-S., Rhyu, D. Y., & Kim, K. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.122108 · Cited by 6 · see citing works

Encountering Pharmacogenetic Test Results in the Psychiatric Clinic

Bousman, C., Mukerjee, G., Men, X., Dorfman, R., Müller, D. J., & Thomas, R. E. (2021) · The Canadian Journal of Psychiatry · doi:10.1177/07067437211058847 · Cited by 6 · see citing works

Morusin as a drug candidate: opportunities, limitations, and the path toward clinical translation

Azzam, H. N., El‐Dessouki, A. M., Attallah, K. A., Sadek, M. A., Aboulmagd, Y. M., Hassan, M.-A. M., Fahmy, M. I., El‐Shiekh, R. A., Kamal, R. M., & Khalifa, H. O. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704535 · Cited by 5 · see citing works

Comparative pharmacokinetic study of six lignans in normal and diabetic rats after oral administration of Saururus chinensis extract by LC–MS/MS

Chen, H., Luo, Y., Liu, J., Chen, J., Chen, Y., & Li, X. (2021) · Biomedical Chromatography · doi:10.1002/bmc.5253 · Cited by 5 · see citing works

Changed regulation of granulocyte NADPH oxidase activity in the mouse model of obesity-induced type 2 diabetes mellitus

Tikhonova, I. V., Dyukina, A. R., Grinevich, A. A., Shaykhutdinova, E. R., & Safronova, V. G. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.03.006 · Cited by 4 · see citing works

Effect of CYP2C19 genotype on outcomes of treatment with ticagrelor versus clopidogrel in acute coronary syndrome patients with diabetes mellitus: A analysis in a large-scale, real-world study

Tian, H., Qiu, M., Na, K., Qi, Z., Xu, K., Liu, H., Wang, X., Li, J., Li, Y., & Han, Y. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177546 · Cited by 4 · see citing works

FAM3D inhibits gluconeogenesis in high glucose environment via DUSP1 / ZFP36 / SIK1 axis

Huang, B., Luo, Y., Huang, J., Li, G., Qiu, S., & Huang, C. (2022) · The Kaohsiung Journal of Medical Sciences · doi:10.1002/kjm2.12633 · Cited by 4 · see citing works

Cytochrome P450 3A gene family in gastric cancer: Unveiling diagnostic biomarkers and therapeutic targets for personalized treatment

Zhu, J., & Wang, J. (2025) · World Journal of Clinical Oncology · doi:10.5306/wjco.v16.i4.101548 · Cited by 3 · see citing works

CYP450 network shifts in MASLD/MASH: from pathogenesis to nutrition-informed modulation

Koç, S., Toydemir, S., Vardar, G., Öter, G. N., & Yusufoğlu, B. (2026) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2026.110459 · Cited by 3 · see citing works

Elevated serum C1q is an independent predictor of high residual platelet reactivity in CAD patients receiving clopidogrel therapy

Zhao, Z., Ma, M., Huang, X., Sun, T., Han, K., Yang, S., & Zhou, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.969984 · Cited by 3 · see citing works

Cannabinoid Receptor 2 Agonism Demonstrates Therapeutic Potential in Experimental Models of Relevance to Diabetic Retinopathy

Ontko, C. D., Smith, T. E., Stark, A. K., Olson, J. C., Newkirk, I. M., Jackson, A. L., McCollum, G. W., & Penn, J. S. (2025) · Diabetes · doi:10.2337/db24-0805 · Cited by 3 · see citing works

To explore pharmacodynamic substances and mechanism of Xuanfei Baidu Decoction on LPS-induced ALI / ARDS by pharmacochemistry and metabolomics

Wang, X., Chen, Z., Li, G., Luo, L., Dong, W., Zhang, L., Yao, B., Zhang, J., & Liu, D. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.119043 · Cited by 2 · see citing works

Type 2 diabetes mellitus as a state of altered drug pharmacokinetic-pharmacodynamic parameters: an update on recent developments and clinical implications

Sibiya, N. H., Onyekwuluje, C., Kuretu, A., Ayodele, O., Ngcobo, N., Ngubane, P. S., & Khathi, A. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188241305021 · Cited by 2 · see citing works

Cytochrome P450

Bhatia, K. S., Mahesh, A. N., & Bhatt, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824315-2.00696-5 · Cited by 2 · see citing works

Investigation of the Expression of CYP3A4 in Diabetic Rats in Xenobiotic Metabolism

GÜVEN, N. M., Karaömerlioğlu, İ., Arioglu‐Inan, E., & Eke, B. C. (2023) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2023.87450 · Cited by 1 · see citing works

Case Report: Severe SIADH and QTc prolongation induced by escitalopram-quetiapine interaction in a CYP2C19 intermediate metabolizer at therapeutic doses

蒋宗辰, Qu, X., Yan, Z., Fang, J., Lan, J., Zhao, X., & Qi, W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1776959 · Cited by 1 · see citing works

Effects of Adjuvant Medications on A1C, Body Mass Index, and Insulin Requirements among Patients with Type 1 Diabetes

Almodóvar, A. S., Clevenger, J., & Nahata, M. C. (2022) · Pharmacy · doi:10.3390/pharmacy10040097 · Cited by 1 · see citing works

Pharmacogenetics of CYP2C19*17: Functional and Clinical Implications of CYP2C19*17 - rs12248560 (c.-806C>T) in the Development of Type 2 Diabetes

Elfaki, I., Mir, R., Tayeb, F. J., Barnawi, J., Alalawy, A. I., Mirghani, H. O., Alshammari, S. E., & Dabla, P. K. (2022) · Biomedical & Pharmacology Journal · doi:10.13005/bpj/2528 · Cited by 1 · see citing works

What is the impact of metabolic dysfunction–associated steatotic liver disease on drug transport and metabolism?

Dietrich, C. G., & Geier, A. (2024) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2024.2324015 · Cited by 1 · see citing works

CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study

El-Maraghy, H. M., Al-Adl, M., Saifeldein, E. R., Elashmony, S. M., Youssef, M. M., Elsaid, A. M. M., Refaat, S., & Mohammed, A. E. (2025) · Frontiers in Bioscience-Scholar · doi:10.31083/fbs36269

Additional file 1 of Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report

Del Toro-Pagán, N. M., Matos, A., Bardolia, C., Michaud, V., Turgeon, J., & Amin, N. S. (2022) · Figshare · doi:10.6084/m9.figshare.18849369

Additional file 2 of Pharmacist assessment of drug-gene interactions and drug-induced phenoconversion in major depressive disorder: a case report

Del Toro-Pagán, N. M., Matos, A., Bardolia, C., Michaud, V., Turgeon, J., & Amin, N. S. (2022) · Figshare · doi:10.6084/m9.figshare.18849372

EFFECT OF SARS-CoV-2 ON CYTOCHROME P450-DEPENDENT METABOLISM OF DRUG: A REVIEW

(2025) · Biolohichni systemy · doi:10.31861/biosystems2025.02.238

Enhancing dental implant outcomes in type 2 diabetes: Addressing inflammation and risk factors

Xiao, L.-F., Xing, Y.-X., & Sun, N. (2026) · World Journal of Diabetes · doi:10.4239/wjd.v17.i2.113906

Several antiplatelet gene SNPs, their haplotypes and G × E interactions on premature coronary artery disease

Bi, Z.-H., Liu, S.-C., Weng, Y.-H., Chen, J.-Y., Li, S. X., Lin, X.-Q., Liu, Y., & Miao, L. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1875319

Pharmacogenetics and Pharmacogenomics in Psychiatry: Challenges and Opportunities

(2026) · Frontiers research topics · doi:10.3389/978-2-8325-8475-0

Inflammation-Induced Phenoconversion of Polymorphic Drug Metabolizing Enzymes: Hypothesis with Implications for Personalized Medicine

Shah, R. R., & Smith, R. L. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.114.061093 · Cited by 196 · see citing works

Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case–control pharmacokinetic study

Gravel, S., Chiasson, J., Dallaire, S., Turgeon, J., & Michaud, V. (2018) · BMJ Open · doi:10.1136/bmjopen-2017-020922 · Cited by 16 · see citing works

Modulation of CYP 450 Activities in Patients With Type 2 Diabetes

Gravel, S., Chiasson, J., Turgeon, J., Grangeon, A., & Michaud, V. (2019) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1496 · Cited by 84 · see citing works

Evaluation of important human CYP450 isoforms and P‐glycoprotein phenotype changes and genotype in type 2 diabetic patients, before and after intensifying treatment regimen using Geneva cocktail

Neyshaburinezhad, N., Shirzad, N., Rouini, M. R., Namazi, S., Khoshayand, M. R., Esteghamati, A., Nakhjavani, M., Ghasim, H., Gloor, Y. S., Daali, Y., et al. (2023) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13840 · Cited by 9 · see citing works

Drug Metabolizing Enzymes in Type II Diabetes and their Pharmacogenetics During Therapy of Anti-Diabetes Drugs

Chakraborty, C., Hsu, M. J., & Agoramoorthy, G. (2015) · Current Drug Metabolism · doi:10.2174/138920021610151210183821 · Cited by 4 · see citing works